Cargando…
Treatment capacity required for full‐scale implementation of lung cancer screening in the United States
BACKGROUND: Full‐scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers. METHODS: A well‐established microsimulation model was extended with treatment data from the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541509/ https://www.ncbi.nlm.nih.gov/pubmed/30811590 http://dx.doi.org/10.1002/cncr.32026 |
_version_ | 1783422782128783360 |
---|---|
author | Blom, Erik F. ten Haaf, Kevin Arenberg, Douglas A. de Koning, Harry J. |
author_facet | Blom, Erik F. ten Haaf, Kevin Arenberg, Douglas A. de Koning, Harry J. |
author_sort | Blom, Erik F. |
collection | PubMed |
description | BACKGROUND: Full‐scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers. METHODS: A well‐established microsimulation model was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack‐years (US Preventive Services Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 77 years, with a smoking history of at least 30 pack‐years (Centers for Medicare and Medicaid Services [CMS] recommendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, with a smoking history of at least 40 pack‐years (the most cost‐effective policy in Ontario [Ontario]). The base‐case screening adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50% between 2018 and 2027. RESULTS: The USPSTF policy would require 37.0% more lung cancer surgeries in 2015‐2040 than no screening, 2.2% less radiotherapy, and 5.4% less chemotherapy; 5.7% more patients would require any therapy. The increase in surgical demand would be 96.1% in 2018, 46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. By 2018, surgical demand would range from 52,619 (20% adherence) to 96,121 (80%). With a gradual buildup of adherence, the increase in surgical demand would be 9.6% in 2018, 38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies were similar, although the changes in comparison with no screening were smaller. CONCLUSIONS: Full‐scale implementation of lung cancer screening causes a major increase in surgical demand, with a peak within the first 5 years. A gradual buildup of adherence can spread this peak over time. Careful surgical capacity planning is essential for successfully implementing screening. |
format | Online Article Text |
id | pubmed-6541509 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65415092019-06-17 Treatment capacity required for full‐scale implementation of lung cancer screening in the United States Blom, Erik F. ten Haaf, Kevin Arenberg, Douglas A. de Koning, Harry J. Cancer Original Articles BACKGROUND: Full‐scale implementation of lung cancer screening in the United States will increase detection of early stages. This study was aimed at assessing the capacity required for treating those cancers. METHODS: A well‐established microsimulation model was extended with treatment data from the National Cancer Database. We assessed how treatment demand would change when implementing lung cancer screening in 2018. Three policies were assessed: 1) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 80 years, with a smoking history of at least 30 pack‐years (US Preventive Services Task Force [USPSTF] recommendations); 2) annual screening of current smokers and former smokers who quit fewer than 15 years ago, aged 55 to 77 years, with a smoking history of at least 30 pack‐years (Centers for Medicare and Medicaid Services [CMS] recommendations); and 3) annual screening of current smokers and former smokers who quit fewer than 10 years ago, aged 55 to 75 years, with a smoking history of at least 40 pack‐years (the most cost‐effective policy in Ontario [Ontario]). The base‐case screening adherence was a constant 50%. Sensitivity analyses assessed other adherence levels, including a linear buildup to 50% between 2018 and 2027. RESULTS: The USPSTF policy would require 37.0% more lung cancer surgeries in 2015‐2040 than no screening, 2.2% less radiotherapy, and 5.4% less chemotherapy; 5.7% more patients would require any therapy. The increase in surgical demand would be 96.1% in 2018, 46.0% in 2023, 38.3% in 2028, and 24.9% in 2040. Adherence strongly influenced results. By 2018, surgical demand would range from 52,619 (20% adherence) to 96,121 (80%). With a gradual buildup of adherence, the increase in surgical demand would be 9.6% in 2018, 38.3% in 2023, 42.0% in 2028, and 24.4% in 2040. Results for the CMS and Ontario policies were similar, although the changes in comparison with no screening were smaller. CONCLUSIONS: Full‐scale implementation of lung cancer screening causes a major increase in surgical demand, with a peak within the first 5 years. A gradual buildup of adherence can spread this peak over time. Careful surgical capacity planning is essential for successfully implementing screening. John Wiley and Sons Inc. 2019-02-27 2019-06-15 /pmc/articles/PMC6541509/ /pubmed/30811590 http://dx.doi.org/10.1002/cncr.32026 Text en © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Blom, Erik F. ten Haaf, Kevin Arenberg, Douglas A. de Koning, Harry J. Treatment capacity required for full‐scale implementation of lung cancer screening in the United States |
title | Treatment capacity required for full‐scale implementation of lung cancer screening in the United States |
title_full | Treatment capacity required for full‐scale implementation of lung cancer screening in the United States |
title_fullStr | Treatment capacity required for full‐scale implementation of lung cancer screening in the United States |
title_full_unstemmed | Treatment capacity required for full‐scale implementation of lung cancer screening in the United States |
title_short | Treatment capacity required for full‐scale implementation of lung cancer screening in the United States |
title_sort | treatment capacity required for full‐scale implementation of lung cancer screening in the united states |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541509/ https://www.ncbi.nlm.nih.gov/pubmed/30811590 http://dx.doi.org/10.1002/cncr.32026 |
work_keys_str_mv | AT blomerikf treatmentcapacityrequiredforfullscaleimplementationoflungcancerscreeningintheunitedstates AT tenhaafkevin treatmentcapacityrequiredforfullscaleimplementationoflungcancerscreeningintheunitedstates AT arenbergdouglasa treatmentcapacityrequiredforfullscaleimplementationoflungcancerscreeningintheunitedstates AT dekoningharryj treatmentcapacityrequiredforfullscaleimplementationoflungcancerscreeningintheunitedstates |